The management of unresectable stage III non–small cell lung cancer has entered a more individualized era, shaped by advances in radiation delivery, consolidation immunotherapy, molecular testing, and targeted treatment.
In a state-of-the-art review published in the American Society of Clinical Oncology Educational Book, Parth Desai, Martin J. Edelman, and Sameera Kumar examine the evidence guiding current treatment and the strategies being investigated to improve long-term outcomes.
Concurrent chemoradiotherapy remains the foundation of curative-intent treatment. However, the decisions surrounding that foundation have become increasingly precise. Tumor biology, molecular alterations, radiation technique, performance status, and recurrence risk now influence the treatment pathway from diagnosis through consolidation and follow-up.
A Curative Setting With Persistent Risk
Approximately 25% to 30% of patients with NSCLC present with locally advanced stage III disease.
Some patients are considered unresectable because of bulky or multistation N2 disease, N3 lymph-node involvement, or extensive local invasion. Others are medically inoperable because of poor pulmonary function, cardiovascular comorbidities, advanced age, or other clinical factors.
For patients with good performance status and unresectable disease, concurrent chemoradiotherapy remains the standard definitive approach. Despite its curative intent, historical outcomes have remained limited, with only about 30% of patients surviving 5 years.
The treatment objective is therefore twofold: eradicate visible locoregional disease and reduce the risk of subsequent local and distant relapse.
The First Treatment Decision Begins Before Chemoradiotherapy
Stage III NSCLC is a clinically and biologically heterogeneous diagnosis. Accurate staging and multidisciplinary evaluation are essential before treatment begins.
Recommended assessment includes contrast-enhanced computed tomography of the chest and upper abdomen, positron emission tomography, and central nervous system imaging with brain magnetic resonance imaging. Contrast-enhanced head CT may be used when MRI is contraindicated.
Patients being considered for curative-intent treatment also require accurate pathological mediastinal lymph-node staging, preferably through endoscopic techniques and, less commonly, surgical mediastinoscopy.
Determining whether disease is resectable requires input from an experienced thoracic surgeon. In selected cases, resectability may need to be reconsidered as the patient moves through treatment.
Every patient with stage III NSCLC should therefore be evaluated through a multidisciplinary tumor board whenever feasible.
Biomarker Testing Moves to the Beginning of Care
Molecular testing is no longer reserved for metastatic disease.
Up-front assessment for EGFR exon 19 deletions and exon 21 L858R mutations has become essential because EGFR status directly determines the preferred consolidation strategy after chemoradiotherapy.
PD-L1 testing also informs treatment planning. Whenever feasible, broader molecular profiling should assess additional actionable genomic alterations, including ALK, ROS1, RET, MET, HER2/ERBB2, and KRAS G12C.
Evidence supporting targeted consolidation for alterations other than EGFR remains limited. Nevertheless, identifying these alterations at diagnosis may influence future treatment decisions, clinical trial eligibility, and management at recurrence.
Tumor-based multigene panel testing is preferred when available. Liquid biopsy may help accelerate testing, although its reported sensitivity in stage III NSCLC is approximately 45%. A positive plasma result has high specificity and strong concordance with tumor testing.
Chemoradiotherapy Remains the Backbone
For patients with an Eastern Cooperative Oncology Group performance status of 0 or 1, concurrent chemoradiotherapy remains the standard of care.
Sequential platinum-based chemotherapy followed by definitive radiotherapy may be considered for patients with limited performance status, including selected patients with ECOG performance status 2. Radiotherapy alone is used less frequently, while patients unable to receive definitive radiation may be treated according to approaches used for metastatic NSCLC.
The standard radiation dose remains 60 to 66 Gy, delivered in fractions of 1.8 to 2.0 Gy over approximately 6 to 6.5 weeks, together with platinum-based doublet chemotherapy.
The superiority of concurrent over sequential treatment was established through trials including RTOG 9410. Concurrent therapy improved median overall survival from 14.6 to 17.0 months and increased 5-year overall survival from 10% to 16%, although it was associated with greater acute toxicity.
Why More Radiation Is Not Always Better
Attempts to improve outcomes through uniform radiation-dose escalation have not produced the expected benefit.
In the phase III RTOG 0617 trial, patients receiving 74 Gy experienced inferior survival compared with those receiving 60 Gy. At a median follow-up of 5.1 years, median overall survival was 28.7 months with 60 Gy and 20.3 months with 74 Gy.
Higher-dose treatment was also associated with greater dysphagia and esophagitis. Subsequent analyses identified cardiac radiation exposure and acute treatment-related toxicity as important contributors to the poorer outcomes.
These findings established that increasing radiation dose across the entire treatment volume does not necessarily improve disease control and may compromise survival when normal tissues receive excessive exposure.
Interest has consequently shifted toward selective intensification. Stereotactic body radiotherapy boosts to residual primary tumors or dominant nodal disease are being evaluated as a more focused method of increasing dose to high-risk areas.
The ongoing NRG LU-008 trial is comparing the standard PACIFIC-based approach with a strategy incorporating SBRT to the primary tumor before conventional treatment of affected lymph nodes.
Radiation Becomes More Precise
Intensity-modulated radiotherapy has become the preferred radiation technique for unresectable stage III NSCLC because it can improve treatment conformality while reducing exposure to the lungs, heart, esophagus, and spinal cord.
A secondary analysis of RTOG 0617 found that grade 3 or higher pneumonitis occurred in 3.5% of patients treated with intensity-modulated radiotherapy compared with 8.2% of those receiving three-dimensional conformal radiotherapy.
Intensity-modulated treatment also reduced the volume of the heart receiving at least 40 Gy. Heart V40 was 16.5% with intensity-modulated radiotherapy and 20.5% with three-dimensional conformal radiotherapy.
Cardiac exposure has emerged as an important determinant of long-term outcomes. Treatment planning must therefore balance adequate tumor coverage with strict protection of the heart and other organs at risk.
Managing a Tumor That Moves
Respiratory motion presents a particular challenge during thoracic radiotherapy.
Four-dimensional CT simulation, respiratory gating, breath-hold techniques, abdominal compression, surface tracking, and daily image guidance can improve tumor localization and reduce unnecessary treatment margins.
Four-dimensional CT divides the respiratory cycle into multiple phases, allowing clinicians to visualize the full range of tumor movement during breathing. This information helps ensure that the target remains covered while limiting radiation exposure to healthy lung tissue.
Daily cone-beam CT and other image-guided techniques also improve setup accuracy and help account for anatomical changes between treatment sessions.
Adaptive Radiotherapy Responds to Change
Tumors and surrounding anatomy may change considerably during the 6-week course of chemoradiotherapy.
Tumor regression, changes in atelectasis, pleural effusions, and weight loss can alter the dose delivered to both the tumor and nearby organs. Approximately 10% of patients with stage III NSCLC may require replanning because of tumor-volume changes or other anatomical developments.
Traditional mid-treatment resimulation can improve treatment accuracy but is resource-intensive and may interrupt care. New adaptive radiotherapy platforms are being developed to account for daily anatomical changes without requiring a treatment break.
Early data suggest that adaptive treatment may reduce pneumonitis, although randomized evidence supporting routine implementation remains limited.
Future strategies may incorporate biological imaging, including PET-CT, to intensify treatment in resistant tumor regions while reducing dose in areas showing a strong response.
Selecting the Chemotherapy Partner
Several platinum-based chemotherapy regimens can be combined with definitive radiotherapy.
Common options include cisplatin plus etoposide and weekly carboplatin plus paclitaxel across histological subtypes. For nonsquamous disease, cisplatin plus pemetrexed or carboplatin plus pemetrexed may be considered.
The PROCLAIM trial compared cisplatin-pemetrexed with cisplatin-etoposide in 598 patients with nonsquamous NSCLC. Median overall survival was similar at 26.8 months and 25.0 months, respectively.
The findings supported cisplatin-pemetrexed as an effective option for nonsquamous disease, with a potentially more favorable toxicity profile.
Carboplatin may be used in patients who are not eligible for cisplatin, although outcomes with carboplatin are generally considered inferior.
PACIFIC Established a New Post-Treatment Standard
Historically, more than 60% to 70% of patients experienced recurrence after definitive chemoradiotherapy, with distant relapse occurring in almost half.
Earlier attempts to reduce this risk through additional consolidation chemotherapy did not produce consistent survival benefits and increased toxicity.
The phase III PACIFIC trial changed that standard.
The trial included 713 patients whose disease had not progressed after definitive concurrent chemoradiotherapy. Participants received consolidation durvalumab or placebo.
Durvalumab improved median progression-free survival from 5.6 to 16.8 months, corresponding to a hazard ratio of 0.52. Median overall survival increased from 29.1 to 47.5 months, with a hazard ratio of 0.72.
At 5 years, overall survival was 42.9% with durvalumab and 33.4% with placebo.
Durvalumab is now the established consolidation treatment for patients without EGFR-mutated disease who have no progression after definitive chemoradiotherapy. In the United States, it is used regardless of PD-L1 expression. In Europe, its indication applies to patients with a tumor-cell PD-L1 score of at least 1%.
Treatment should ideally begin within 42 days after completion of chemoradiotherapy and continue for up to 12 months or until disease progression or unacceptable toxicity.
Pneumonitis occurred in approximately one third of patients, although grade 3 or higher events were reported in about 4% to 5% and were comparable between the study groups.
Evidence from PACIFIC-6 and PACIFIC-5 also suggests that consolidation durvalumab may provide benefit after sequential chemoradiotherapy in patients who are unable to receive concurrent treatment.
Concurrent Immunotherapy Fails to Improve the Standard
The success of consolidation durvalumab raised the question of whether immune checkpoint inhibition could be started during chemoradiotherapy.
Trials evaluating this approach have not demonstrated improved outcomes.
PACIFIC-2 and EA5181 investigated durvalumab administered concurrently with chemoradiotherapy, followed by consolidation treatment. Neither study showed an improvement in progression-free or overall survival, while toxicity increased.
Grade 3 pneumonitis rates ranged from approximately 7% to 11% in studies using concurrent immune checkpoint inhibition.
Similar results were reported with concurrent and maintenance nivolumab compared with maintenance durvalumab.
Current evidence therefore supports immune checkpoint inhibition after completion of chemoradiotherapy rather than during definitive radiation treatment.
EGFR Status Creates a Separate Treatment Path
The phase III LAURA trial established a different consolidation strategy for patients with EGFR-mutated unresectable stage III NSCLC.
The trial enrolled 216 patients with EGFR exon 19 deletions or L858R mutations whose disease had not progressed after definitive chemoradiotherapy. Participants received osimertinib at 80 mg once daily or placebo.
Osimertinib reduced the risk of disease progression or death by 84%, with a hazard ratio of 0.16.
Median progression-free survival was 39.1 months with osimertinib and 5.6 months with placebo.
The treatment also produced a substantial central nervous system benefit. New brain metastases developed in 8% of patients receiving osimertinib compared with 29% of those receiving placebo.
Grade 3 or higher adverse events were reported in 35% of the osimertinib group and 12% of the placebo group. Treatment discontinuation remained relatively low at 13%.
Interstitial lung disease or pneumonitis was reported in 56% of patients receiving osimertinib and 38% of those receiving placebo.
Unlike durvalumab, which is administered for up to 12 months, osimertinib in LAURA was continued until progression or unacceptable toxicity without a predetermined stopping point.
The most recent overall survival update reported a median overall survival of 58.8 months in the osimertinib group and 54 months in the placebo group, with 31% data maturity. The placebo result was likely influenced by the use of EGFR-targeted therapy after progression, as 81% of patients in the placebo group subsequently received osimertinib.
Recurrence Requires a New Multidisciplinary Assessment
Approximately half of patients treated with definitive chemoradiotherapy followed by durvalumab experience disease progression within 5 years.
Management depends on the location, volume, timing, histology, and molecular characteristics of the recurrence.
Comprehensive restaging with PET and central nervous system imaging is essential. Repeat tissue or plasma genomic profiling is strongly recommended, particularly when broad molecular testing was not completed at diagnosis.
Patients with isolated locoregional recurrence may be considered for salvage surgery, reirradiation, or endobronchial treatment in carefully selected cases.
Approximately 50% of relapses may involve fewer than three progressive sites. These patients may be candidates for local ablative treatment, including SBRT or metastasectomy, together with systemic therapy.
The role of immunotherapy rechallenge after prior durvalumab remains uncertain. Retrospective evidence suggests that patients who experienced a durable initial response of at least 12 months may derive greater benefit than those with early progression.
Clinical trial participation remains particularly important because no single standard has been established for many post-durvalumab recurrence scenarios.
The Search for a Better Consolidation Strategy
Despite the improvement produced by PACIFIC, 5-year overall survival remains approximately 43%, leaving substantial room for further progress.
Several studies are examining whether durvalumab can be strengthened through combination therapy.
The phase II COAST trial reported encouraging response and progression-free survival findings when durvalumab was combined with the anti-CD73 antibody oleclumab or the anti-NKG2A antibody monalizumab.
These combinations are being evaluated in the phase III PACIFIC-9 trial. PACIFIC-8 is assessing durvalumab with the anti-TIGIT antibody domvanalimab.
Other approaches have been less successful. Tiragolumab plus atezolizumab did not improve progression-free or overall survival over durvalumab in SKYSCRAPER-03. The combination of vibostolimab and pembrolizumab also failed to demonstrate a meaningful survival benefit.
ROSETTA Lung-201 is evaluating the PD-L1 and VEGF bispecific antibody pumitamig against durvalumab as post-chemoradiotherapy maintenance.
Can Earlier Immune Treatment Improve Outcomes?
Induction chemotherapy before chemoradiotherapy previously failed to improve survival and increased toxicity. However, those studies were conducted before the introduction of immune checkpoint inhibitors.
Current research is examining whether immune treatment given before chemoradiotherapy can activate antitumor immunity while the intact tumor remains present.
In the phase II APOLO trial, induction atezolizumab with carboplatin and paclitaxel was followed by concurrent chemoradiotherapy and maintenance atezolizumab. The 12-month progression-free survival rate was 68.4%, while 12-month overall survival reached 86.8%.
The randomized phase II InTRist trial evaluated induction toripalimab plus platinum-based chemotherapy before chemoradiotherapy, followed by consolidation toripalimab.
One-year progression-free survival was 85.6% with induction toripalimab plus chemotherapy and 54.5% with chemotherapy alone, corresponding to a hazard ratio of 0.26.
These findings are encouraging, but induction immune treatment remains investigational. Prospective trials directly comparing these strategies with the established PACIFIC approach are required.
Induction treatment may also have a role in selected patients with borderline resectable disease. In an early cohort from the MDT-Bridge trial, 20 of 28 patients, or 71%, underwent successful surgical resection after neoadjuvant chemoimmunotherapy. However, the definition of borderline resectability was not reported and may have included a heterogeneous population.
Extending Targeted Treatment Beyond EGFR
The success of osimertinib has increased interest in consolidation targeted therapy for other actionable genomic alterations.
Prospective evidence remains limited, particularly for ALK-positive disease. However, a multicenter retrospective study found longer real-world progression-free survival with an ALK tyrosine kinase inhibitor, predominantly alectinib, than with durvalumab.
Progression-free survival was 11.3 months with ALK-targeted treatment and 7.2 months with durvalumab, with a hazard ratio of 0.12.
HORIZON 1 is prospectively evaluating targeted consolidation strategies, including alectinib for ALK-positive disease and entrectinib for ROS1-positive disease, against maintenance durvalumab.
The study may help define whether biomarker-directed treatment should replace immune checkpoint inhibition for additional oncogene-driven stage III tumors.
A More Individualized Standard
The treatment of unresectable stage III NSCLC is no longer defined by chemoradiotherapy alone.
Concurrent chemoradiotherapy with 60 to 66 Gy remains the definitive foundation for fit patients, while modern radiation techniques improve normal-tissue protection and treatment accuracy.
The post-chemoradiotherapy pathway is now divided by tumor biology. Durvalumab remains the consolidation standard for patients without sensitizing EGFR mutations, while osimertinib is preferred for patients with EGFR exon 19 deletions or L858R mutations.
Up-front molecular testing, multidisciplinary evaluation, precise radiation planning, and careful treatment sequencing have become central components of care.
Ongoing studies are now addressing the remaining questions: whether induction treatment can improve immune activation, whether selective radiation intensification can strengthen local control, and whether additional oncogene-driven tumors can benefit from targeted consolidation.
Written by Nare Hovhannisyan, MD
Explore more oncology news and features on OncoDaily.